Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms.

Inhibition of platelet activation by nitric oxide (NO) is not exclusively cGMP-dependent. Here, we tested whether inhibition of platelet aggregation by structurally distinct NO donors is mediated by different mechanisms, partly determined by the site of NO release. Glyceryl trinitrate (GTN), sodium nitroprusside (SNP), S-nitrosoglutathione (GSNO), diethylamine diazeniumdiolate (DEA/NO), and a novel S-nitrosothiol, RIG200, were examined in ADP (8 microM)- and collagen (2.5 microgram/ml)-activated human platelet rich plasma. GTN was a poor inhibitor of aggregation whilst the other NO donors inhibited aggregation, irrespective of agonist. These effects were abolished by the NO scavenger, hemoglobin (Hb; 10 microM, P < 0.05, n = 6), except with high concentrations of DEA/NO, when NO concentrations exceeded the capacity of Hb. However, experiments with the soluble guanylate cyclase inhibitor, ODQ (100 microM), indicated that only SNP-mediated inhibition was exclusively cGMP-dependent. Furthermore, the cGMP-independent effects of S-nitrosothiols were distinct from those of DEA/NO, suggesting that different NO-related mediators (e.g., nitrosonium and peroxynitrite, respectively) are responsible for their actions.

[1]  J. Loscalzo,et al.  Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. , 1999, The Journal of clinical investigation.

[2]  M. Raida,et al.  Inhibition of platelet aggregation by S‐nitroso‐cysteine via cGMP‐independent mechanisms: evidence of inhibition of thromboxane A2 synthesis in human blood platelets , 1999, FEBS letters.

[3]  D. Wink,et al.  Stability of S-nitrosothiols in presence of copper, zinc-superoxide dismutase. , 1999, Methods in enzymology.

[4]  M. A. Moro,et al.  Nitric oxide-dependent and independent effects on human platelets treated with peroxynitrite. , 1998, Cardiovascular research.

[5]  C. Garland,et al.  Nitric oxide (NO)‐induced activation of large conductance Ca2+‐dependent K+ channels (BKCa) in smooth muscle cells isolated from the rat mesenteric artery , 1998 .

[6]  J. Hothersall,et al.  Evidence for a cyclic GMP‐independent mechanism in the anti‐platelet action of S‐nitrosoglutathione , 1998, British journal of pharmacology.

[7]  B. Freeman,et al.  Xanthine Oxidase-mediated Decomposition ofS-Nitrosothiols* , 1998, The Journal of Biological Chemistry.

[8]  Z. Katušić,et al.  The effect of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and charybdotoxin (CTX) on relaxations of isolated cerebral arteries to nitric oxide , 1998, Brain Research.

[9]  Z. Liu,et al.  S-Transnitrosation reactions are involved in the metabolic fate and biological actions of nitric oxide. , 1998, The Journal of pharmacology and experimental therapeutics.

[10]  J. Stamler,et al.  Cell-free and erythrocytic S-nitrosohemoglobin inhibits human platelet aggregation. , 1998, Circulation.

[11]  D. Webb,et al.  Prolonged effect of a novel S‐nitrosated glyco‐amino acid in endothelium‐denuded rat femoral arteries: potential as a slow release nitric oxide donor drug , 1997, British journal of pharmacology.

[12]  S. Sage,et al.  The Wellcome Prize Lecture. Calcium entry mechanisms in human platelets , 1997, Experimental physiology.

[13]  Randy S. Lewis,et al.  Measurement and modeling of nitric oxide release rates for nitric oxide donors. , 1997, Chemical research in toxicology.

[14]  J. Vostal,et al.  Peroxynitrite-induced tyrosine nitration and phosphorylation in human platelets. , 1997, Free radical biology & medicine.

[15]  J. Hothersall,et al.  Role of a copper (I)‐dependent enzyme in the anti‐platelet action of S‐nitrosoglutathione , 1996, British journal of pharmacology.

[16]  K. Schrör,et al.  Biotransformation of glyceryl trinitrate by blood platelets as compared to vascular smooth muscle cells. , 1996, European journal of pharmacology.

[17]  A. Butler,et al.  Identification of Cu+ as the effective reagent in nitric oxide formation from S-nitrosothiols (RSNO) , 1996 .

[18]  I. Lizasoain,et al.  The formation of nitric oxide donors from peroxynitrite , 1995, British journal of pharmacology.

[19]  J. Garthwaite,et al.  Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. , 1995, Molecular pharmacology.

[20]  J. Loscalzo,et al.  Glutathione peroxidase potentiates the inhibition of platelet function by S-nitrosothiols. , 1995, The Journal of clinical investigation.

[21]  J. Hothersall,et al.  Copper chelation‐induced reduction of the biological activity of S‐nitrosothiols , 1995, British journal of pharmacology.

[22]  F. W. Flitney,et al.  Chemical mechanisms underlying the vasodilator and platelet anti-aggregating properties of S-nitroso-N-acetyl-DL-penicillamine and S-nitrosoglutathione. , 1995, Bioorganic & medicinal chemistry.

[23]  R. Cohen,et al.  Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle , 1994, Nature.

[24]  R. Ross.  The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[25]  L. Keefer,et al.  Nitric Oxide/Nucleophile Complexes: A Unique Class of Nitric Oxide‐Based Vasodilators , 1993, Journal of cardiovascular pharmacology.

[26]  J. Stamler,et al.  Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Stamler,et al.  S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Stamler,et al.  The antiplatelet effects of organic nitrates and related nitroso compounds in vitro and in vivo and their relevance to cardiovascular disorders. , 1991, Journal of the American College of Cardiology.

[29]  A. Hassid,et al.  Nitric oxide decreases cytosolic free calcium in Balb/c 3T3 fibroblasts by a cyclic GMP-independent mechanism. , 1991, The Journal of biological chemistry.

[30]  S. Moncada,et al.  An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S Moncada,et al.  The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. , 1987, Biochemical and biophysical research communications.

[32]  S. Moncada,et al.  ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM , 1987, The Lancet.

[33]  S. Moncada,et al.  The anti‐aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide , 1987, British journal of pharmacology.

[34]  S. Moncada,et al.  Comparative pharmacology of endothelium‐derived relaxing factor, nitric oxide and prostacyclin in platelets , 1987, British journal of pharmacology.

[35]  J. Abrams.  Pharmacology of nitroglycerin and long-acting nitrates. , 1985, The American journal of cardiology.

[36]  R. Furchgott,et al.  Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. , 1985, The Journal of pharmacology and experimental therapeutics.

[37]  J. Mehta,et al.  Comparative Effects of Nitroprusside and Nitroglycerin on Platelet Aggregation in Patients with Heart Failure , 1980, Journal of cardiovascular pharmacology.